Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.
- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.
- In the cohort of patients with gynecologic tumors, the RECIST response was 50%, OR was 60%, and CBR was 70%.
- These patients also had a median of 3 and up to 9 prior lines of therapy, before administration of lunresertib.
- RP-3467 is Repare’s wholly-owned Polθ inhibitor, currently in IND-enabling studies, which began in the second quarter of 2023 and remain ongoing.